Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

Litigation Details for Genzyme Corporation v. Gland Pharma Limited (D. Del. 2018)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Genzyme Corporation v. Gland Pharma Limited (D. Del. 2018)

Docket   Start Trial Date Filed 2018-07-19
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Kent A. Jordan
Jury Demand None Referred To
Patents 6,987,102; 7,897,590; RE42,152
Attorneys Dominick T. Gattuso; Jeffrey B. Bove; Karen R. Poppel
Firms Heyman Enerio Gattuso & Hirzel LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Genzyme Corporation v. Gland Pharma Limited
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Genzyme Corporation v. Gland Pharma Limited (D. Del. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-07-19 1 Complaint the ’590 patent”), and 6,987,102 (“the ’102 patent”) arising under the Patent Laws of the United States…152 patent, the ’590 patent, and the ’102 patent based on Gland’s contention that the ’152 patent, the…is an action for patent infringement of U.S. Patent Nos. RE42,152 (“the ’152 patent”), 7,897,590 (“the…least some claims of the ’152 patent, the ’590 patent, and the ’102 patent. Moreover, Plaintiff Sanofi … The ’152 patent, the ’590 patent, and the ’102 patent cover the use of Mozobil® according to its Approved External link to document
0000-00-00 4 Patent/Trademark Report to Commissioner of Patents E; US 7,897,590 B2; US 6,987,102 B2. (ceg) (Entered: 07/19/2018) 19 July 2018 PACER Document … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US RE42,152 E;… 19 July 2018 1:18-cv-01071 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.